NCT06529926

Brief Summary

Instrument-assisted soft tissue mobilization is an instrument-assisted soft tissue mobilization technique. It consists of stainless steel instrument designed to adapt to various tissues/shapes/curves of the body. The instruments were developed as an alternative to transverse friction massage. Stainless steel acts a bit like a diaposon when it comes into contact with fibrotic tissue. A resonance or reverberation in the instrument is created upon contact and transmitted through the instrument to the hands of the clinician. The application of heavy pressure (compared to light or medium pressure) using instruments has been proven to promote a greater fibroblastic response. Instrument-assisted soft tissue mobilization is not used without insulation. It is imperative to use movement and strengthening in combination with soft tissue mobilization to promote tissue adaptation and remodeling. Mechanical loading has been shown to affect chondrocyte alignment and fibroblast activity with increased proteoglycan and collagen synthesis. The aim of this study was to investigate the effects of the IASTM technique on individuals of different ages diagnosed with LDH.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Nov 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2017

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2018

Completed
5.6 years until next milestone

First Submitted

Initial submission to the registry

July 21, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 31, 2024

Completed
Last Updated

July 31, 2024

Status Verified

July 1, 2024

Enrollment Period

1.1 years

First QC Date

July 21, 2024

Last Update Submit

July 26, 2024

Conditions

Outcome Measures

Primary Outcomes (18)

  • Evaluation of Pain

    Visual analog scale was used to evaluate the pain of the patients.

    Pre-treatment assessment.

  • Evaluation of Pain

    Visual analog scale was used to evaluate the pain of the patients.

    After 4 weeks of treatment (Post-treatment assessment).

  • Evaluation of Pain

    Visual analog scale was used to evaluate the pain of the patients.

    2nd month post-treatment assessment.

  • Evaluation of Functional Status (Straight leg raise test)

    Straight leg raise test was used to evaluate the functional status of the patients.

    Pre-treatment assessment.

  • Evaluation of Functional Status (Straight leg raise test)

    Straight leg raise test was used to evaluate the functional status of the patients.

    After 4 weeks of treatment (Post-treatment assessment).

  • Evaluation of Functional Status (Straight leg raise test)

    Straight leg raise test was used to evaluate the functional status of the patients.

    2nd month post-treatment assessment.

  • Evaluation of Functional Status (Slump test)

    Slump test was used to evaluate the functional status of the patients.

    Pre-treatment assessment.

  • Evaluation of Functional Status (Slump test)

    Slump test was used to evaluate the functional status of the patients.

    After 4 weeks of treatment (Post-treatment assessment).

  • Evaluation of Functional Status (Slump test)

    Slump test was used to evaluate the functional status of the patients.

    2nd month post-treatment assessment.

  • Evaluation of Functional Status (5-min walking test)

    5-min walking test was used to evaluate the functional status of the patients.

    Pre-treatment assessment.

  • Evaluation of Functional Status (5-min walking test)

    5-min walking test was used to evaluate the functional status of the patients.

    After 4 weeks of treatment (Post-treatment assessment).

  • Evaluation of Functional Status (5-min walking test)

    5-min walking test was used to evaluate the functional status of the patients.

    2nd month post-treatment assessment.

  • Evaluation of Normal Joint ROM

    Goniometer was used to evaluate the normal joint ROM of the patients.

    Pre-treatment assessment.

  • Evaluation of Normal Joint ROM

    Goniometer was used to evaluate the normal joint ROM of the patients.

    After 4 weeks of treatment (Post-treatment assessment).

  • Evaluation of Normal Joint ROM

    Goniometer was used to evaluate the normal joint ROM of the patients.

    2nd month post-treatment assessment.

  • Evaluation of Quality of Life

    Short Form-36 was used to evaluate the quality of life of the patients.

    Pre-treatment assessment.

  • Evaluation of Quality of Life

    Short Form-36 was used to evaluate the quality of life of the patients.

    After 4 weeks of treatment (Post-treatment assessment).

  • Evaluation of Quality of Life

    Short Form-36 was used to evaluate the quality of life of the patients.

    2nd month post-treatment assessment.

Study Arms (2)

Control Group

OTHER

Treated with classical physiotherapy (Hotpack+TENS+Ultrasound) program. A 20-minute hotpack was applied to the lumbar area. TENS and ultrasound were applied as electrotherapy agents. The TENS application was made with the Chattanooga Intelect Advanced Combo device. Conventional tens was applied at a frequency of 100 Hz for 20 min with a current of 100 μs. The ultrasound application was made with the Chattanooga Intelect Advanced Combo device. Lumbar area was administered at a dose of 1 MHz, 1.5 W/cm² using a 5 cm diameter cap for 6 min. In the first session, the physiotherapist had the patient explain the exercises (posterior pelvic tilt exercise, hip flexors stretching exercise, lumbar extensors stretching exercise, abdominal muscle strengthening exercise, SLR exercise, pelvic elevation exercise, cat-camel exercise and lumbar extensor strengthening exercise). Afterwards, patients were advised to rest for 1 minute between exercises, 1 time a day and for 4 weeks, 5 days a week.

Other: Observational

IASTM Treatment Group

EXPERIMENTAL

IASTM application was applied at an angle of 45° in a direction parallel to the muscle fibers for about 20 seconds. Immediately afterwards, a total of 40 seconds of treatment time was applied by treating the muscle fibers at a 45° angle with the instrument for an additional 20 seconds in a direction perpendicular to them. In other words, for each area (paraspinal muscles, gluteus maximus and gluteus medius muscles, hamstrings), a total of 2 minutes was applied to the right and left sides separately for 40x3 seconds. Paraspinal muscles were treated from caudal to cranium, gluteal muscles from proximal to distal and hamstring muscles from popliteal fossa to gluteal line. Stretching was provided by exercises applied to the control group. After the cold application, IASTM application was made, the cold-pack was applied to each area for 5 minutes. (The application was performed by a trained and experienced physiotherapist and with a stainless steel gua sha device).

Other: IASTM Technique Application

Interventions

Only classical physiotherapy application for 4 weeks.

Control Group

IASTM application for 2 sessions per week with classical physiotherapy for 4 weeks.

IASTM Treatment Group

Eligibility Criteria

Age20 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Individuals have been diagnosed with LDH,
  • Their pain is 3 and above according to the Visual Analog Scale (VAS),
  • They are between the ages of 20-60,
  • Their clinical status is stable,
  • They are fully cooperative,
  • They do not have cognitive, cognitive and mental problems and they can express themselves,
  • They voluntarily agree to participate in the study.

You may not qualify if:

  • Individuals have psychological disorders, mental disorders, cancer and severe depression,
  • Primary or metastatic spinal malignancy,
  • Have been diagnosed with advanced osteoporosis,
  • Have recently undergone surgical intervention or acute infection,
  • Cannot or do not want to perform tests or treatment exercises,
  • Want to leave voluntarily.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Inonu University

Malatya, 44280, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Motor ActivityPain

Interventions

Watchful Waiting

Condition Hierarchy (Ancestors)

BehaviorNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Outcome Assessment, Health CareOutcome and Process Assessment, Health CareQuality of Health CareHealth Services Administration

Study Officials

  • Muhammed Üsame TAŞ, Lecturer

    Inonu University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 21, 2024

First Posted

July 31, 2024

Study Start

November 1, 2017

Primary Completion

December 1, 2018

Study Completion

December 31, 2018

Last Updated

July 31, 2024

Record last verified: 2024-07

Data Sharing

IPD Sharing
Will not share

Locations